Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: Results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1654-1660

  Yokota, Shumpei ^a,b   Itoh, Yasuhiko ^a,c   Morio, Tomohiro ^a,d   Origasa, Hideki ^a,e   Sumitomo, Naokata ^a,f   Tomobe, Minako ^g   Tanaka, Kunihiko ^g   Minota, Seiji ^a,h  

^a Chugai Tocilizumab JIA Safety Evaluation Comittee   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

^f SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

DMARDs (biologic); Juvenile Idiopathic Arthritis; Treatment

Indexed keywords

C REACTIVE PROTEIN; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; AGE; ARTICLE; BACTERIAL PNEUMONIA; BRONCHITIS; CARDIOVASCULAR DISEASE; CELLULITIS; CHICKENPOX; CHILD; DISEASE DURATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EYE DISEASE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HERPES ZOSTER; HISTIOCYTOSIS; HUMAN; IMMUNOPATHOLOGY; INFLUENZA; INFUSION RELATED REACTION; JAPAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PEDIATRICS; PHARYNGITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SCHOOL CHILD; SEPSIS; SKIN DISEASE; SYMPTOM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; ARTHRITIS, JUVENILE; REGISTER; TIME FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84954304921     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207818     Document Type: Article

References (27)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49.
2. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012;12:56-9.
3. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991;17:891-905.
4. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep 2014;6:21,21. eCollection 2014.
5. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
6. Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2012;2012:271569.
7. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
8. Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005;28:231-8.
9. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:R1281-8.
10. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
11. Yokota S, Kishimoto T. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 2010;6:735-43.
12. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
13. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
14. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
15. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51.
16. Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014;41:15-23.
17. Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014;41:759-67.
18. Minoia F, Davi S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66:3160-9.
19. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
20. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133-8.
21. Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr 2011;63:459-66.
22. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001;40:1285-92.
23. Kostik MM, Dubko MF, Masalova VV, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum 2015;44:417-22.
24. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007;19:477-81.
25. Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 2015;42:712-22.
26. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-303.
27. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365:82-93.